Navigation Links
Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
Date:2/23/2013

SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ -- Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma™ program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. In prespecified subgroups from two paired clinical trials, tiotropium delivered once daily via the Respimat® inhaler improved lung function and asthma control, as defined by a decrease in asthma exacerbations or worsening of asthma, in patients with poorly controlled asthma, irrespective of their allergic status. Patients included in the study remained symptomatic despite current treatment with at least high dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).

"Patients with asthma may respond differently to treatment based on their allergic status, therefore it is important to investigate new therapies in both allergic and non-allergic patients," said Mark Vandewalker , MD, director, Clinical Research of the Ozarks, Columbia, Missouri. "The results of these trials show that tiotropium provides additional bronchodilation and reduces exacerbation rates in asthmatics who are uncontrolled on current therapy with at least ICS/LABA regardless of their allergic status, thus demonstrating its potential benefit for patients who need additional asthma control."

The two PrimoTinA-asthma™ studies were replicate double-blind parallel-group trials including asthma patients with post-bronchodilator FEV1 less than 80 percent predicted and asthma control questionnaire score of greater than or equal to 1.5, while on at least high dose ICS/LABA. A total of 912 patients were randomized to receive tiotropium 5 mcg or placebo in addition to usual care for 48 weeks. In addition to ICS/LABA, patients in the trials were permitted to receive additional background t
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas , Nov. 21, 2014  World Hemp ... containing low THC, announces they are now offering legal, ... to Charlotte,s Web type strains grown in medical marijuana ... other neurological disorders, such as Parkinson,s, MS, and spinal ... US laws to pass, because imported CBD Oil Is ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... Nov. 20, 2014  Market research firm Kalorama information says ... The Buy, in the medical device industry.  The firm ... will produce just 3% growth this year, which led ... of product lines and entrance by acquisition into new ... medical devices, The Global Market for Medical Devices, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... HONG KONG, Feb. 25, 2011 /PRNewswire-Asia-FirstCall/ -- Golden ... - 801.HK; 910801.TW), China,s leading integrated healthcare enterprise, ... acquire the remaining interests in the Group,s Chinese ... HK$90 million in shares.  Upon completion of the ...
... Calif., Feb. 24, 2011 Amgen (Nasdaq: AMGN ... 3 head-to-head trial that compared XGEVA ™ (denosumab) to ... skeletal-related events (SREs) in 1,901 men with prostate cancer and ... met its primary and secondary endpoints and demonstrated XGEVA,s superiority ...
Cached Medicine Technology:Golden Meditech Acquires Remaining Stake in Chinese Herbal Medicine Business 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 3Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 4Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 5Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 6Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 7Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 8Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 9
(Date:11/23/2014)... November 23, 2014 The FDA is ... Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? Any ... The FDA’s focus on promotional activities is no longer ... Now they're looking at websites, Twitter, journal articles, TV ... for Thursday, Dec. 11, for On-Demand access to Timothy ...
(Date:11/23/2014)... 23, 2014 BambooFlooringChina.com , the world’s ... click strand woven bamboo flooring collection. Now, the business ... the company’s CEO, the promotion is valid until Dec. 20, ... with a smooth and dust-free surface, which makes it very ... the industry, the company wants to make its website the ...
(Date:11/22/2014)... A new AlignLife Chiropractic & Natural ... downtown Greenville area. Dr. Chelsea Sineath, owner and chiropractor ... open her own clinic after working in another AlignLife ... , AlignLife believes that the body can heal ... on chiropractic care and rehabilitation to allow the spine ...
(Date:11/22/2014)... November 23, 2014 Recently, UWDress.com, a successful ... formal wedding guest attire in order to prepare for ... prices, up to 70% off. , UWDress.com is a ... are very beautiful, especially the new items -- formal wedding ... in the current market, including superstar and princess. As one ...
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the ... new collection of bamboo mats ; the new models ... , According to the sales manager of BambooFlooringChina.com, ... a highly renewable resource. Their bamboo mats are 100% made ... comes from natural bamboo with caramel bamboo strips. ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2
... ... company, now offers their clients a choice between a Flat Fee Plan and a Monthly ... Miami, FL ... cash strapped plaintiffs don’t have to wait for their lawsuits to recover, they can get ...
... NASHVILLE, Tenn., Dec. 10 Pathological gambling can be ... inhibitions, according to researchers at the annual meeting of ... outcomes in gamblers treated with medications often used for ... his team at the University of Minnesota used tasks ...
... The 2009 American College of Neuropsychopharmacology Annual Meeting ... schizophrenia and treatment for gambling addiction. Study highlights ... Techniques to Assess PTSD. Working with Iraq and ... may be useful to evaluate PTSD and develop ...
... ... a leading neurologist, Dr. Alexander Mauskop, renowned headache expert and founder of the New ... ... 9, 2009 -- A powerful headache medicine developed by a leading neurologist for his ...
... , WARRINGTON, Pa., Dec. 9 Last year Special Equestrians was ... part of $25,000 in PR service grants. "We,ve always taken corporate ... a warm and fuzzy feeling to do what little we can ... co-founder, Christopher L. Simmons. "We learned many years ago that it ...
... Award Will Create New Construction and Permanent Jobs in the South ... Additional 12,000 Residents , NEW YORK, Dec. 9 ... Reinvestment Act (Recovery Act) grant to support a new addition to ... announced by President Barack Obama as part of his plan to ...
Cached Medicine News:Health News:Injury Funds Now To the Rescue with New Lawsuit Funding Service 2Health News:Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction 2Health News:Late-breaking brain and behavior research presented at ACNP annual meeting this week 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 3Health News:Nonprofit Partners With PR Company and Gains International Attention 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: